Abstract:During the last 20 years, the renin-angiotensin system (RAS) has become an increasingly important focus of basic and clinical cardiovascular research. One main conceptual step forward was made with the discovery of a tissue RAS and the understanding of its critical pathophysiological role in atherogenesis and plaque destabilisation. Major effort to find new strategies for blocking the RAS has produced new classes of drugs which were expected to be clinically important in the management of hypertension and heart failure. As landmark clinical studies have demonstrated that inhibition of the RAS significantly reduces morbidity and mortality from coronary heart disease, myocardial infarction and heart failure, the concept has rapidly emerged that blocking the RAS was the strategy of choice for preventing cardiovascular diseases. More recently, basic research has however continuously extended our understanding of the complexity of the systemic and tissue RASs, that can no longer be viewed as one-way streets in which one single effector, angiotensin II acts solely through its major (AT1) receptor. Meanwhile, clinical trials have challenged the concept that blocking the RAS is the most effective preventive strategy for all patients and all target organs. Consistent with the recent understanding that the RAS encompasses a number of distinct effectors acting through different receptors to promote opposite effects, a growing body of basic and clinical evidence suggests that blunting the RAS is a double-edge sword, with beneficial effects counterbalanced by deleterious ones, resulting in a net effect that critically depends on the experimental conditions, or the clinical characteristics of the study population. Of particular clinical relevance, a number of clinical trials point to the somewhat provocative conclusion that beyond their blood pressure lowering effect antihypertensive drugs that decrease angiotensin II formation are less stroke protective than the ones that increase angiotensin levels. This review focuses on the recent experimental evidence demonstrating that angiotensin II and its derivatives acting through the non-AT1 receptors are involved in protective mechanisms against cerebral ischaemia and discusses in the light of the recent large cardiovascular prevention trials the clinical relevance of this new concept. The perspective of a renewal of therapeutical strategies to optimise the prevention of target organ damage and perhaps even some of the diseases of ageing, such as loss of cognitive function is emphasised.

Functions and regulation of brain renin-angiotensin system in early development

Involvement of the Brain (Pro) Renin Receptor in Cardiovascular Homeostasis

Development of Fetal Brain Renin–angiotensin System and Hypertension Programmed in Fetal Origins

The Renin-Angiotensin System in the Central Nervous System and Its Role in Blood Pressure Regulation

MICROGLIAL ACTIVATION BY THE BRAIN RENIN‐ANGIOTENSIN SYSTEM

Brain Microglial Cytokines are Critical for Renin-Angiotensin-Aldoterone-System(RAAS)-Induced Neurogenic Hypertension

Physiology and Pathophysiology of the Intrarenal Renin-Angiotensin System: an Update

Targeting the Renin-Angiotensin-Aldosterone System to Prevent Hypertension and Kidney Disease of Developmental Origins

Kidney Renin–Angiotensin System: Lost in a RAS Cascade

Mechanism of renin-angiotensin-aldosterone system inhibitors

The Central Renin Angiotensin II System – a Genetic Pathway, Functional Decoding and Selective Target Engagement Characterization in Humans

In Utero Development of Central ANG-stimulated Pressor Response and Hypothalamic Fos Expression.

Programming the cardiovascular system, kidney and the brain--a review

The role of the brain renin-angiotensin system in Parkinson ́s disease

Prenatal LPS leads to increases in RAS expression within the PVN and overactivation of sympathetic outflow in offspring rats

Brain Transforming Growth Factor-Beta Resists Hypertension Via Regulating Microglial Activation

The renin-angiotensin-aldosterone system (RAAS) - physiology and molecular mechanisms of functioning

The brain and hypertension: how the brain regulates and suffers from blood pressure

The renin-angiotensin-aldosterone system: An old tree sprouts new shoots

The Renin-Angiotensin Systems: Evolving Pharmacological Perspectives for Cerebroprotection

Central angiotensin I increases swallowing activity and oxytocin release in the near-term ovine fetus.